.Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01D_CytotoxicAntibioticsAndRelatedSubstances.L01DB09_Valrubicin.Valrubicin .Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01D_CytotoxicAntibioticsAndRelatedSubstances.L01DB09_Valrubicin.Valrubicin| name: | Valrubicin | |
| ATC code: | L01DB09 | route: | intravesical |
| compartments: | 1 | |
| dosage: | 800 | mg |
| volume of distribution: | 325 | L |
| clearance: | 78.6 | L/h |
| other parameters in model implementation | ||
Valrubicin is a semisynthetic anthracycline derivative used as an antineoplastic agent, primarily for the intravesical treatment of Bacillus Calmette-Guerin (BCG)-refractory carcinoma in situ of the urinary bladder. It is approved for this indication and is not recommended for systemic administration.
Pharmacokinetic data are reported for adults with BCG-refractory carcinoma in situ of the bladder following intravesical administration.